BRIEF-Cell Therapeutics expects to get $67 mln in cash milestone payments from Baxter through 2015 - SEC filing

Mon Nov 18, 2013 6:24am EST

Nov 18 (Reuters) - Cell Therapeutics Inc : * Expects could pay up to $96 million in development costs for persist-1 & 2

myelofibrosis & acute myeloid leukemia programs till mid-2017 * Under Baxter deal co expects to receive $67 million in cash milestone

progress payments from Baxter through 2015 - SEC filing * Source text for Eikon * Further company coverage

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.